top of page


3 February 2023

Cargene is honored to be featured as one of the seven globally selected companies on Clarivate's "RNA Technology Companies to Watch" report. Our mention in this article speaks volumes about our innovative and proprietary technological platforms used to develop treatments for a broad range of indications such as liver and ophthalmic disorders. 

Cargene is continuously committed to accelerating therapeutic development by combining novel biology with proprietary nucleic acid technology and delivery platforms to address high unmet medical needs and improve lives. 

Our sincerest thanks to Clarivate for this feature! 

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report (

28 June 2022

We are delighted to welcome Kathy He, newly appointed CEO and a member of the Board of Cargene Biopharma. Kathy is a seasoned and insightful biopharmaceutical industry executive.

For the past over 20 years, she has been instrumental in the growth of multiple global companies, leading many successful strategic collaborations and fundraising events with her extensive US and China cross-border business leadership experience in start-ups and MNCs.

As the team progresses onward and upward, we look forward to seeing Kathy’s integration and working with her to drive towards growth and success!

Welcome Kathy!!

Cargene Biopharma Welcomes Kathy He as CEO, to Accelerate Novel Oligonucleotide Therapeutics Development

14 December 2021

We are delighted to announce the closing of our US$19.2M Pre-A Round, which we will use to accelerate nucleic acid therapeutics through innovative chemistry and biology to improve lives worldwide.

Cargene Closes a US$19.2M Pre-A Round Led by BioTrack Capital 

bottom of page